Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23401461 | 0.86 | LMNA (0.57) | LMNATSHRCNR1CNR2GAA | |
| SCHEMBL23399441 | 0.86 | KDM5A (0.41) | LMNATSHRALDH1A1L3MBTL1NPC1 | |
| SCHEMBL23399975 | 0.83 | ALDH1A1 (0.47) | LMNAGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL23401774 | 0.83 | CNR1 (0.62) | LMNATSHRCNR1CNR2ALDH1A1 | |
| SCHEMBL31522195 | 0.82 | RXRA (0.46) | LMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL28188414 | 0.82 | ALDH1A1 (0.41) | TSHRALDH1A1 | |
| SCHEMBL28729848 | 0.81 | CNR1 (0.45) | LMNATSHRCNR1CNR2GAA | |
| SCHEMBL23400074 | 0.81 | CACNA1H (0.47) | CNR1CNR2GAAALDH1A1 | |
| SCHEMBL1013253 | 0.80 | CYP1A2 (0.61) | LMNATSHRCNR1CNR2GAA | |
| SCHEMBL15869371 | 0.80 | ALDH1A1 (0.60) | LMNATSHRGAAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058611-A | 1-Aryl-5-pyrazolone compound, and pharmaceutical composition and application thereof | 中国药科大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-119930520-A | N-aryl pyrazole compound, and pharmaceutical composition and application thereof | 中国药科大学 | 2025-05-06 | — | — | CN | disclosed |
| EP-3828159-A1 | STORAGE AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2021-06-02 | — | — | EP | disclosed |
| US-10011581-B2 | Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-9725448-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-9676742-B2 | Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170066764-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20150291546-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-8962864-B2 | Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-24 | — | — | US | disclosed |
| US-8853427-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130211098-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-08-15 | — | — | US | disclosed |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211098-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUNDS | CYP4B1, P2RX5, MECP2 | LMNA 1583/4885TSHR 1829/4885CNR1 2049/4885 |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LMNA 410/4885TSHR 983/4885CNR1 498/4885 |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LMNA 491/4885TSHR 1101/4885CNR1 459/4885 |
| US-10011581-B2 | Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound | CYP4B1, P2RX5, P2RX6 | LMNA 1758/4885TSHR 1935/4885CNR1 2055/4885 |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | LMNA 384/4885TSHR 801/4885CNR1 679/4885 |
| US-20150291546-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUND | CYP4B1, KDM4B, MECP2 | LMNA 1784/4885TSHR 2201/4885CNR1 2175/4885 |
| US-20170066764-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | LMNA 384/4885TSHR 801/4885CNR1 679/4885 |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LMNA 491/4885TSHR 1101/4885CNR1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.